Denmark and Norway advise doctors to limit Ozempic use due to high demand for weight loss.

Denmark and Norway have advised doctors to limit the use of Ozempic, a diabetes drug, due to high demand caused by its use for weight loss. The Danish Patient Safety Authority has asked doctors to restrict the number of packs patients can collect at once, while Norway will require doctors to seek cost reimbursements for each individual patient. Both countries have seen a surge in demand for the drug after it was found to contain the same active ingredient as Novo's popular Wegovy obesity drug, semaglutide.

June 24, 2024
12 Articles